전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved73 programs
AntibodyCurated CoreFDAJohnson & JohnsonApproved

nipocalimab (Imaavy, M281, nipocalimab-aahu)

Generalized myasthenia gravis (AChR or MuSK antibody-positive, age ≥12); warm autoimmune hemolytic anemia · FcRn

#FcRn#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 27Status Approved
ADCStandard DatabasestaleGSKcys-mcMMAFPhase 3

belantamab mafodotin (Blenrep, GSK2857916)

Primary Immune Thrombocytopenia (ITP) · Multiple Myeloma

#MultipleMyeloma#ADC#Phase3#Popular#antibody-drug-conjugate+4
Trials 73Status Recruiting
ADCLimited DatastaleGSKPhase 2

Belantamab (Belantamab)

Autoimmune Diseases · Autoimmune Diseases

#AutoimmuneDiseases#ADC#Phase2#Popular#antibody-drug-conjugate+2
Trials 52Status Recruiting
CGTStandard DatabasestaleIncyte CorporationPhase 2

Immune effector cell therapy (Immune effector cell therapy)

Cytokine Release Syndrome · Cytokine Release Syndrome

#CytokineReleaseSyndrome#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 41Status Active
CGTLimited DatastaleViroMissile, Inc.Phase 1

oncolytic vaccinia virus (IDOV-Immune, IDOV-Immune (oncolytic vaccinia virus))

Colorectal Cancer; Pancreatic Cancer · Colorectal Cancer

#ColorectalCancer#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 40Status Recruiting
AntibodyLimited DatastaleSanofiPhase 3

Isatuximab SAR650984 (Isatuximab SAR650984)

Immune System Disorder · Plasma Cell Myeloma

#PlasmaCellMyeloma#Antibody#Phase3#monoclonal-antibody#ImmuneSystemDisorder+2
Trials 39Status Active
CGTStandard DatabasestaleLiaoning Medical Diagnosis and …Phase 2

Autologous immune Cells (Autologous immune Cells)

Lung Cancer (Locally Advanced or Metastatic); Liver Cancer (Locally Advanced or Metastatic) · Lung Cancer (Locally Advanced or Metasta

#LungCancerLocallyAdvancedorMetas#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 31Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

Anti-BCMA-CD19 CAR-T cells (Anti-BCMA-CD19 CAR-T cells)

IgG4 Related Disease; B-cell Mediated Autoimmune Disorders · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 30Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

4SCAR T cells (4SCAR T cells)

Breast Cancer · Autoimmune Diseases

#AutoimmuneDiseases#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 14Status Recruiting
CGTLimited DatastaleXi'niao BiotechPhase 1

universal allogeneic anti-CD19/BCMA CAR T-cells (universal allogeneic anti-CD19/BCMA CAR T-cells)

Autoimmune Hemolytic Anemia; CD19/BCMA CAR T-cells · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 12Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

4SCAR-GD2 (4SCAR-GD2)

Solid Tumor · GD2

#GD2#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 5Status Recruiting
CGTLimited DatastaleThe Children's Hospital of Zhej…Phase 1

KN5601 (anti-CD19/BCMA CAR NK cells, anti-CD19/BCMA CAR NK cells (KN5601))

Autoimmune Diseases; Systemic Lupus Erthematosus · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 5Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

4SCAR-PSMA T cells (4SCAR-PSMA T cells)

PSMA Positive Tumors or Tumor Tissues · PSMA

#PSMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 4Status Active
CGTLimited DatastaleYake Biotechnology Ltd.Phase 1

Assigned Interventions CD19/BCMA CAR T-cells (Assigned Interventions CD19/BCMA CAR T-cells)

Systemic Lupus Erythematosus; Autoimmune Diseases · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 4Status Active
CGTLimited DatastaleShenzhen Genocury Biotech Co., …Preclinical

CD19/BCMA-targeted CAR-T lentiviral vector drug (CD19/BCMA-targeted CAR-T lentiviral vector drug)

Autoimmune Diseases · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 4Status Recruiting
CGTLimited DatastaleThe First Affiliated Hospital o…Preclinical

Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis. (Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.)

Autoimmune Diseases · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 3Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 1

CD20/BCMA-directed CAR-T cells (CD20/BCMA-directed CAR-T cells)

Systemic Lupus Erythematosus (SLE); Immune-mediated Necrotizing Myopathy (IMNM) · CD20

#CD20#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Recruiting
CGTLimited DatastaleNovatim Immune Therapeutics (Zh…Phase 2

KQ-2003 CAR T-cells (KQ-2003 CAR T-cells)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 3Status Active
CGTLimited DatastaleAnhui Provincial HospitalPreclinical

Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis. (Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis.)

Autoimmune Diseases · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 2Status Recruiting
CGTLimited DatastaleNeoImmuneTechPhase 1

CAR T-cell therapy (CAR T-cell therapy)

Large B-cell Lymphoma · Large B-cell Lymphoma

#LargeB-cellLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 2Status Active

1 / 4 pages

← PreviousNext →